captopril has been researched along with meropenem in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bai, Y; Gan, M; Gao, R; Guan, Y; He, W; Li, L; Li, Y; Liu, Y; Xiao, C; You, X; Yu, L | 1 |
| Carlsen, TJ; Christopeit, T; Helland, R; Leiros, HK | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Christopeit, T; Leiros, HK | 1 |
| Bai, W; Cheng, K; Gao, Y; Guo, H; He, W; Li, C; Li, Z; Wu, C | 1 |
| Breeze, AL; Gao, N; Hu, J; Ma, J; MacCormack, K; McLeod, S; Sriram, S | 1 |
| Arakawa, Y; Jin, W; Kimura, K; Kurosaki, H; Mori, S; Wachino, J; Yamaguchi, Y | 1 |
| Albert, A; Christopeit, T; Leiros, HS | 1 |
| Han, J; Hu, F; Liang, Y; Meng, Z; Sun, X; Tang, ML; Yu, JM; Yu, L; Zhang, C | 1 |
| Dai, Y; Gao, Y; Li, H; Li, J; Liu, Y; Sun, K; Yue, C; Zhang, H; Zhao, D | 1 |
1 review(s) available for captopril and meropenem
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for captopril and meropenem
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Polyketides with New Delhi metallo-β-lactamase 1 inhibitory activity from Penicillium sp.
Topics: Alkaloids; beta-Lactamase Inhibitors; beta-Lactamases; China; Circular Dichroism; Crystallography, X-Ray; Inhibitory Concentration 50; Molecular Structure; Penicillium; Polyketides; Quinolones; Rhizosphere | 2013 |
Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Crystallography, X-Ray; Drug Design; Drug Resistance, Bacterial; Humans; Models, Molecular; Pseudomonas aeruginosa; Pseudomonas Infections; Small Molecule Libraries; Surface Plasmon Resonance | 2015 |
Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Dose-Response Relationship, Drug; Drug Discovery; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Surface Plasmon Resonance | 2016 |
A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.
Topics: Anti-Bacterial Agents; beta-Lactamases; Coordination Complexes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Klebsiella pneumoniae; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Surface Plasmon Resonance; Zinc | 2020 |
Real-time monitoring of New Delhi metallo-β-lactamase activity in living bacterial cells by 1H NMR spectroscopy.
Topics: Anti-Bacterial Agents; beta-Lactamases; Captopril; Drug Resistance, Bacterial; Edetic Acid; Enzyme Inhibitors; Escherichia coli; Hydrolysis; Magnetic Resonance Spectroscopy; Meropenem; Spermine; Thienamycins | 2014 |
Structural Insights into Recognition of Hydrolyzed Carbapenems and Inhibitors by Subclass B3 Metallo-β-Lactamase SMB-1.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; beta-Lactamases; Captopril; Carbapenems; Catalytic Domain; Crystallography, X-Ray; Doripenem; Imipenem; Meropenem; Mesna; Protein Structure, Secondary; Protein Structure, Tertiary; Serratia marcescens; Thienamycins | 2016 |
Discovery of a novel covalent non-β-lactam inhibitor of the metallo-β-lactamase NDM-1.
Topics: beta-Lactamase Inhibitors; beta-Lactamases; Captopril; Catalytic Domain; Drug Discovery; Enzyme Activation; Kinetics; Meropenem; Models, Molecular; Mutagenesis, Site-Directed; Spectrometry, Mass, Electrospray Ionization; Surface Plasmon Resonance; Thienamycins | 2016 |
Novel Mercapto Propionamide Derivatives with Potent New Delhi Metallo-β-Lactamase-1 Inhibitory Activity and Low Toxicity.
Topics: Amides; Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Captopril; Cell Line; Cell Survival; Crystallography, X-Ray; Female; Gram-Negative Bacteria; HEK293 Cells; Humans; Inhibitory Concentration 50; Meropenem; Mice; Mice, Inbred ICR | 2019 |
Captopril potentiated meropenem activity against MBL-producing carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study.
Topics: Anti-Bacterial Agents; Antihypertensive Agents; beta-Lactamases; Captopril; Carbapenem-Resistant Enterobacteriaceae; Drug Therapy, Combination; Humans; In Vitro Techniques; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2021 |